Pharma's ambitious antibiotic venture fund makes its first investments; probe into pharma practices expands

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Pharma's ambitious new antibiotic venture fund makes its first investments By Ed Silverman Adobe “This should put the stamp down that we’re up and running and open for business," said Henry Skinner, who runs the AMR Action Fund. Read More STAT+: Wyden wants details on Merck's U.S. taxes as part of expanding probe into pharma practices By Ed Silverman J. Scott Applewhite/AP It appears Merck minimized U.S. profits, while reporting substantial foreign profits to avoid paying U.S. corporate income taxes, Wyden wrote. Read More NIH's cancer chief, Ned Sharpless, to step down By Lev Facher DOULIERY/AFP via Getty Images Sharpless, who spent nearly five years leading the National Cancer Institute within the NIH, will step down at the end of April, he told STAT. Read More Sponsor content by STAT Events A conversation with the STAT Madness crowd favorite Each year, universities and research institutions across the country compete in STAT Madness, a bracket-style tournament, in order to be recognized as having produced the top biomedical innovation or discovery of the year. Register for a virtual event on April 20 to hear researchers from the winning team discuss their work. STAT+: Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible By Ed Silverman Adobe A new government analysis found that broader biosimilar use could have cut Medicare Part D spending on biologic medicines significantly. Read More Monday, April 4, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser